Copyright © Inderes 2011 - present. All rights reserved.
Log in to receive notifications.
NoteHC Andersen Capital has previously received payment from Bavarian Nordic for a Digital IR/Corporate Visibility agreement. This means that there may be paid material that is not updated. See disclaimer.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Bavarian Nordic

154.65

 

DKK

 

+1.05 %

Less than 1K followers

BAVA

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
+1.05%
-2.67%
-21.85%
-18.33%
-29.22%
+3.9%
+18.05%
-4.54%
+8.42%

Bavarian Nordic is a biochemistry company. Today, the company specializes in the development, manufacture, and distribution of vaccines against infectious diseases in connection with cancer treatment. In addition, vaccines against other serious diseases such as Ebola and cervical cancer are also being developed. The largest operations are located in Europe and in the U.S. Bavarian Nordic was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Read more
Market cap
12.19B DKK
Turnover
15.2M DKK
Revenue
5.72B
EBIT %
16.44 %
P/E
12.27
Dividend yield-%
-
Financial calendar
9/5
2025

Interim report Q1'25

22/8
2025

Interim report Q2'25

14/11
2025

Interim report Q3'25

All
Research
Webcasts
Press releases
ShowingAll content types
Regulatory press release4/16/2025, 8:04 PM

Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)

Bavarian Nordic
Regulatory press release4/9/2025, 4:02 PM

Correction: Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S

Bavarian Nordic
Regulatory press release4/9/2025, 3:38 PM

Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S

Bavarian Nordic

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release3/31/2025, 8:37 PM

Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine

Bavarian Nordic
Regulatory press release3/12/2025, 11:00 AM

Bavarian Nordic A/S – Notice Convening Annual General Meeting

Bavarian Nordic
Press release3/7/2025, 6:30 AM

Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older

Bavarian Nordic
Regulatory press release3/5/2025, 7:07 AM

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Bavarian Nordic
Regulatory press release3/5/2025, 6:49 AM

Bavarian Nordic Publishes Annual Report 2024

Bavarian Nordic
Regulatory press release2/28/2025, 4:14 PM

Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older

Bavarian Nordic
Press release2/25/2025, 6:00 AM

Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine

Bavarian Nordic
Regulatory press release2/14/2025, 10:27 PM

Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older

Bavarian Nordic
Regulatory press release2/3/2025, 5:24 PM

Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025

Bavarian Nordic
Regulatory press release1/31/2025, 7:31 PM

Bavarian Nordic – Completion of Share Buy-Back Program

Bavarian Nordic
Regulatory press release1/31/2025, 10:50 AM

Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older

Bavarian Nordic
Regulatory press release1/27/2025, 6:30 AM

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic
Regulatory press release1/20/2025, 6:30 AM

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic
Regulatory press release1/9/2025, 7:09 AM

Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 Million

Bavarian Nordic
Press release12/16/2024, 6:30 AM

Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India

Bavarian Nordic
Regulatory press release12/13/2024, 4:30 PM

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Bavarian Nordic
Regulatory press release12/13/2024, 7:00 AM

New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic

Bavarian Nordic
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Privacy preferences

Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.